These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
347 related articles for article (PubMed ID: 34178414)
41. Critical Considerations for the Design of Multi-Organ Microphysiological Systems (MPS). Malik M; Yang Y; Fathi P; Mahler GJ; Esch MB Front Cell Dev Biol; 2021; 9():721338. PubMed ID: 34568333 [TBL] [Abstract][Full Text] [Related]
42. Organoid and microfluidics-based platforms for drug screening in COVID-19. Ramezankhani R; Solhi R; Chai YC; Vosough M; Verfaillie C Drug Discov Today; 2022 Apr; 27(4):1062-1076. PubMed ID: 34954328 [TBL] [Abstract][Full Text] [Related]
43. Human-Based Advanced Kiener M; Roldan N; Machahua C; Sengupta A; Geiser T; Guenat OT; Funke-Chambour M; Hobi N; Kruithof-de Julio M Front Med (Lausanne); 2021; 8():644678. PubMed ID: 34026781 [TBL] [Abstract][Full Text] [Related]
44. Report of the Assay Guidance Workshop on 3-Dimensional Tissue Models for Antiviral Drug Development. Jordan R; Ford-Scheimer SL; Alarcon RM; Atala A; Borenstein JT; Brimacombe KR; Cherry S; Clevers H; Davis MI; Funnell SGP; Gehrke L; Griffith LG; Grossman AC; Hartung T; Ingber DE; Kleinstreuer NC; Kuo CJ; Lee EM; Mummery CL; Pickett TE; Ramani S; Rosado-Olivieri EA; Struble EB; Wan Z; Williams MS; Hall MD; Ferrer M; Markossian S J Infect Dis; 2023 Oct; 228(Suppl 5):S337-S354. PubMed ID: 37669225 [TBL] [Abstract][Full Text] [Related]
45. Induced pluripotent stem cell-based disease modeling and prospective immune therapy for coronavirus disease 2019. Chakrabarty K; Shetty R; Argulwar S; Das D; Ghosh A Cytotherapy; 2022 Mar; 24(3):235-248. PubMed ID: 34656419 [TBL] [Abstract][Full Text] [Related]
46. 3D organ-on-a-chip: The convergence of microphysiological systems and organoids. Baptista LS; Porrini C; Kronemberger GS; Kelly DJ; Perrault CM Front Cell Dev Biol; 2022; 10():1043117. PubMed ID: 36478741 [TBL] [Abstract][Full Text] [Related]
47. Reconstituted Human Organ Models as a Translational Tool for Human Organ Response: Definition, Expectations, Cases, and Strategies for Implementation in Drug Discovery and Development. Tetsuka K; Ohbuchi M; Kawabe T; Goto T; Kiyonaga F; Takama K; Yamazaki S; Fujimori A Biol Pharm Bull; 2020; 43(3):375-383. PubMed ID: 32115499 [TBL] [Abstract][Full Text] [Related]
48. Application of Human Induced Pluripotent Stem Cell-Derived Cellular and Organoid Models for COVID-19 Research. Luo Y; Zhang M; Chen Y; Chen Y; Zhu D Front Cell Dev Biol; 2021; 9():720099. PubMed ID: 34552930 [TBL] [Abstract][Full Text] [Related]
49. 3D Lung Tissue Models for Studies on SARS-CoV-2 Pathophysiology and Therapeutics. Plebani R; Bai H; Si L; Li J; Zhang C; Romano M Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077471 [TBL] [Abstract][Full Text] [Related]
50. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial. Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543 [TBL] [Abstract][Full Text] [Related]
51. Microphysiological Systems (Tissue Chips) and their Utility for Rare Disease Research. Low LA; Tagle DA Adv Exp Med Biol; 2017; 1031():405-415. PubMed ID: 29214585 [TBL] [Abstract][Full Text] [Related]
52. SARS-CoV-2 infection of primary human lung epithelium for COVID-19 modeling and drug discovery. Mulay A; Konda B; Garcia G; Yao C; Beil S; Sen C; Purkayastha A; Kolls JK; Pociask DA; Pessina P; de Aja JS; Garcia-de-Alba C; Kim CF; Gomperts B; Arumugaswami V; Stripp BR bioRxiv; 2020 Jun; ():. PubMed ID: 32637946 [TBL] [Abstract][Full Text] [Related]
53. Human Organotypic Airway and Lung Organoid Cells of Bronchiolar and Alveolar Differentiation Are Permissive to Infection by Influenza and SARS-CoV-2 Respiratory Virus. Ekanger CT; Zhou F; Bohan D; Lotsberg ML; Ramnefjell M; Hoareau L; Røsland GV; Lu N; Aanerud M; Gärtner F; Salminen PR; Bentsen M; Halvorsen T; Ræder H; Akslen LA; Langeland N; Cox R; Maury W; Stuhr LEB; Lorens JB; Engelsen AST Front Cell Infect Microbiol; 2022; 12():841447. PubMed ID: 35360113 [TBL] [Abstract][Full Text] [Related]
54. 3D Cell Culture Models in COVID-19 Times: A Review of 3D Technologies to Understand and Accelerate Therapeutic Drug Discovery. de Dios-Figueroa GT; Aguilera-Marquez JDR; Camacho-Villegas TA; Lugo-Fabres PH Biomedicines; 2021 May; 9(6):. PubMed ID: 34073231 [TBL] [Abstract][Full Text] [Related]
55. The K18-Human ACE2 Transgenic Mouse Model Recapitulates Non-severe and Severe COVID-19 in Response to an Infectious Dose of the SARS-CoV-2 Virus. Dong W; Mead H; Tian L; Park JG; Garcia JI; Jaramillo S; Barr T; Kollath DS; Coyne VK; Stone NE; Jones A; Zhang J; Li A; Wang LS; Milanes-Yearsley M; Torrelles JB; Martinez-Sobrido L; Keim PS; Barker BM; Caligiuri MA; Yu J J Virol; 2022 Jan; 96(1):e0096421. PubMed ID: 34668775 [TBL] [Abstract][Full Text] [Related]